KLRK1 and plasma cell myeloma: demonstrated that CS1-NKG2D bispecial antibodies facilitate the augmentation of immune synapses between CS1+ multiple myeloma (MM) cells and NKG2D+ cytolytic innate as well as antigen-specific effector cells.